GH Research (NASDAQ:GHRS) Shares Gap Up – Here’s Why

GH Research PLC (NASDAQ:GHRS) shares gapped up before the market opened on Tuesday . The stock had previously closed at $17.99, but opened at $19.19. GH Research shares last traded at $16.65, with a volume of 157,728 shares traded.

Wall Street Analyst Weigh In

A number of equities analysts have commented on GHRS shares. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Monday, January 27th. Canaccord Genuity Group decreased their target price on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th.

GH Research Stock Down 8.1 %

The company has a 50 day moving average of $8.84 and a 200-day moving average of $9.00.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. increased its holdings in GH Research PLC (NASDAQ:GHRS) by 1.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the quarter. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 as of its most recent filing with the Securities & Exchange Commission. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).